Roche restructures its management and appoints a new manager for its ‘pharma’ business

Roche reshuffles its management. The Swiss pharmaceutical company has appointed Teresa Graham, currently head of global product strategy at Roche Farma, as the new CEO of Roche Farma, a position that she will occupy from March 2023.

At the same time, Levi Garraway, chief medical officer and executive vice president of global product development, will become a member of the corporate executive committee. Both will report to the new CEO of the pharmaceutical company, Thomas Schinecker.

Graham started at Genentech in 2005 in product management. She became a sales manager in 2010 before taking over as director of marketing for Rituxan Immunology and later for Actemra. Her responsibilities expanded further in 2013 when she became Senior Director of Field Reimbursement Management and then Lifecycle Leader for Actemra.

Roche will make the appointment of Teresa Graham official from March

In 2017, Graham led important aspects of the Genentech portfolio, owned by Roche, until she was appointed to her current position in 2019 and moved to Basel, Switzerland. A graduate of George Washington University, she is also a global board member of the Association of Women’s Health Entrepreneurs, where she has served in multiple capacities for more than a decade.

For his part, Garraway joined Roche in October 2019 in his current position. Before entering the pharmaceutical industry, he was director of the Joint Center for Precision Medicine in Cancer, which encompassed Harvard University hospitals, including the Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Children’s Hospital Boston, and the Institute Broad from MIT and Harvard.

Throughout his academic career at Dana-Farber, Harvard Medical School, and the Broad Institute, Garraway led research teams that made multiple discoveries in cancer genomics, drug resistance, and precision medicine. He is the author of more than 200 peer-reviewed scientific articles.

The pharmaceutical company achieved a profit of 13,565 million euros in 2022

Garraway is a member of the National Academy of Medicine, a fellow of the American Association for Cancer Research (AACR), and past president of the American Society for Clinical Research. In addition, he has served on the advisory boards of major cancer centers, including Memorial Sloan Kettering and MD Anderson, as well as on various committees of the National Institutes of Health (NIH) and the Blue Ribbon Panel for the Moonshot Initiative against Cancer. beau biden cancer

Roche achieved a profit of 13,531 million Swiss francs (13,565 million euros) in 2022, which translates into a decrease of 9% compared to 2021, according to the latest annual economic results published by the company. The multinational justifies this result by a greater impairment of intangible assets and higher interest costs and taxes on income.